Tirzepatide hits NCE-1 date, opening the door to generic patent challenges
Generic companies can now begin challenging Lilly's tirzepatide patents, but the listed patents and exclusivities point to a real generic arriving in the late 2030s, not soon.
Tirzepatide, the active ingredient in Eli Lilly's Mounjaro and Zepbound, reached its NCE-1 date on May 13, 2026 — the first day a generic manufacturer can file an abbreviated new drug application (ANDA) with a Paragraph IV certification challenging Lilly's Orange Book patents on the molecule [1][2]. The date is a procedural opening for litigation, not a generic launch. Lilly's New Chemical Entity (NCE) exclusivity on tirzepatide still runs to May 13, 2027 [1][2].
NCE exclusivity gives a newly approved active ingredient five years of protection during which the FDA will not accept a generic application that challenges the brand's patents. The NCE-1 date falls one year earlier, four years after first approval, so patent disputes can start before exclusivity lapses [1]. Tirzepatide's first approval was Mounjaro for type 2 diabetes in May 2022, and Zepbound, the weight-loss version, was approved November 8, 2023 [1][3].
The patents being challenged extend well past the exclusivity date. The core compound patent, US 9,474,780, covers the tirzepatide molecule and a broader genus of GLP-1/GIP-targeting compounds. One patent review puts its US expiry at January 5, 2036 [1]; a separate patent-tracking database lists it as expiring in May 2036 [2]. On top of that sit later-listed patents: Zepbound's latest-listed patent (US 12,343,382, methods of use) runs to July 22, 2039, and Mounjaro's latest-listed patent runs to December 30, 2041 [1][2]. Patent analysts cited in the first review estimate the earliest realistic US generic launch at 2036 at the very earliest, and more plausibly 2039 to 2041 once formulation and device patents are counted [1]. The patent database estimates a generic launch date of July 22, 2039 for Zepbound in its autoinjector form [2].
Challenges have already been attempted, without success so far. Empower Clinic Services, doing business as Empower Pharmacy, challenged US 9,474,780 in May 2025, and BPI Labs filed a similar challenge in August 2025. Both drew discretionary denial at the Patent Trial and Appeal Board — in October 2025 and December 2025, respectively [2]. Zepbound also carries four listed exclusivities: New Product to November 8, 2026; NCE to May 13, 2027; M-82 to October 18, 2027; and a new-indication exclusivity to December 20, 2027 [2]. Whether any generic company has filed an ANDA since May 13, 2026, and what Lilly's response has been, has not been reported.
Why it matters for patients
Nothing on a pharmacy shelf changes on a filing date. The NCE-1 milestone does not create a generic tirzepatide, lower a list price, or alter insurance coverage, and no generic version has been approved [1][2].
Cost remains the practical gate. Manufacturer list prices for the brand-name weight-loss drugs run near $1,000 to $1,350 per month before discounts [1]. A Medicare negotiated price for semaglutide — Ozempic, Rybelsus and Wegovy — takes effect January 1, 2027, at roughly $274 per month for Ozempic and Rybelsus and about $386 for Wegovy, under the Inflation Reduction Act, with a separate most-favored-nation agreement bringing Medicare semaglutide to about $245 per month starting in 2026 [1]. Those prices apply to semaglutide, not tirzepatide, and only to defined Medicare populations; a negotiated tirzepatide price has not been announced in these materials [1].
Fewer alternatives exist than headlines about generics abroad suggest. Liraglutide, the older daily GLP-1, is currently the only true generic GLP-1 available in the US, and it is generally considered less effective and less convenient than the weekly semaglutide and tirzepatide injections [1]. Compounded versions were never FDA-approved generics and exist in a shifting legal zone [1]. Brand savings cards and capped copay programs remain the main discount route for commercially insured patients [1].
What happens next
Several dated steps sit between the NCE-1 opening and any generic tirzepatide. Zepbound's New Product exclusivity expires November 8, 2026 [2]. The NCE exclusivity runs out May 13, 2027 [1][2], followed by M-82 exclusivity on October 18, 2027 and a new-indication exclusivity on December 20, 2027 [2]. The semaglutide Medicare negotiated prices take effect January 1, 2027 [1]. None of these dates shortens the compound patent, which [1] dates to January 5, 2036 and [2] lists as May 2036.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.